Expression of stratifin in endometrial cancer and its relationship with clinicopathological features and prognosis
Objective To explore the expression of stratifin(SFN)protein in endometrial cancer and its relationship with the clinico-pathological features and prognosis of the patients.Methods The expression of SFN in endometrial cancer and normal endometrial tissues was analyzed in The Cancer Genome Atlas(TCGA)database.The expression of SFN in 96 endometrial cancer tissue samples and 60 normal endometrial tissue samples collected from the Second Affiliated Hospital of Zhengzhou University from January 2017 to December 2019 was detected by immunohistochemistry,and its relationship with the clinicopathological features and prognosis of the endometrial cancer pa-tients was analyzed.Results The TCGA database analysis and immunohistochemical detection showed that SFN expression in endometrial cancer tissues was significantly higher than that in normal endometrial tissues(both P<0.05),SFN expression in endometrial cancer tissues were significantly different in terms of surgical pathological stage(both P<0.01),and the postoperative disease-free survival(DFS)and overall survival(OS)of the patients with low SFN expression were worse than those of the patients with high SFN expression(both P<0.05).Multivariate analysis by Cox's proportional hazards model showed that histological grade and surgical pathological stage were risk factors for DFS,while histological grade and SFN expression were risk factors for OS(all P<0.05).Conclusions SFN expression in endometrial cancer tissues is higher than that in normal endometrial tissues.Endometrial cancer patients with low SFN expression has a poor prognosis.
万方数据
维普
